AVEIR VR Leadless Pacemaker

Clinical Decision Analysis

Clinical Question

What decision would you make from these 4 options based on the spreadsheet attached that shows the history of an AVEIR VR LP?

Treatment Options:

1. Wait and Watch
2. Implant a new unicameral LP
3. Upgrade to a bicameral removing the existent
4. Do not remove or remove the LP and place a transvenous CSP (Conduction System Pacing) pacemaker
Data Available from AVEIR HISTORICO.xlsx:
Primary Recommendation

Option 1: Wait and Watch (with structured monitoring protocol)

Clinical Rationale

Supporting Evidence for Wait and Watch:

  1. Excellent Battery Longevity: 8-year battery life estimate indicates optimal device function and programming
  2. Stable Electrical Parameters:
    Capture threshold: 1.5V @0.4ms (acceptable range)
    Impedance: 340 ohms (within normal 200-1500 ohm range)
    Sensing: 2.7mV (adequate)
  3. Recent Technology: AVEIR VR represents current-generation leadless pacing; premature replacement should be avoided
  4. Risk-Benefit Analysis: Any intervention carries procedural risks that aren't justified with stable parameters

Recommended Monitoring Protocol

Follow-up Schedule:

  • Every 3-6 months: Remote monitoring or in-office device checks
  • Annual comprehensive evaluation: Complete parameter assessment and trending analysis

Critical Parameters to Monitor:

Capture Threshold: Concerning if consistently >2.5V @0.4ms
Impedance: Alert if <200 ohms or >1500 ohms
Battery Voltage: Track decline rate and longevity estimates
R-wave Sensing: Should remain >5mV for reliable detection
Intervention Triggers

Consider alternative options if any of these develop:

When to Consider Other Options

Option 2 (New Unicameral LP) - Consider if:

  • Capture threshold rises consistently >2.5V @0.4ms
  • Impedance falls <200 ohms or rises >1500 ohms
  • Battery life projection drops to <2 years
  • Device-related complications or infections
  • Sensing issues with R-wave <5mV

Option 3 (Bicameral Upgrade) - Consider if:

  • Patient develops higher-degree AV block requiring dual-chamber pacing
  • New clinical indication for atrial pacing emerges
  • Chronotropic incompetence requiring rate-responsive atrial pacing
  • Pacemaker syndrome symptoms develop

Option 4 (Conduction System Pacing) - Consider if:

  • Heart failure develops with reduced ejection fraction and wide QRS
  • Indication for cardiac resynchronization therapy
  • Preference for physiologic conduction system pacing benefits
  • High percentage of RV pacing with concern for pacing-induced cardiomyopathy

Alternative Considerations

If the complete trending data reveals concerning parameter deterioration not visible in the limited data assessment, Option 2 (new unicameral LP) would be the most appropriate intervention, allowing for:

  • Safe removal of the existing device
  • Fresh system with optimal battery life
  • Updated technology and programming capabilities
  • Continued single-chamber pacing if clinically appropriate
Clinical Note

This analysis is based on limited parameter visibility from the spreadsheet. A complete review of all trending data, patient symptoms, underlying rhythm, exercise capacity, and current clinical status would help refine this recommendation further.

Clinical Decision Support - AVEIR VR Leadless Pacemaker Management

This analysis should be considered alongside complete clinical evaluation and current guidelines